Press Releases Archivi

Nouscom to present interim data from Phase 1 trial evaluating NOUS-209, an ‘off-the-shelf’ neoantigen cancer vaccine for the treatment of MSI-H solid tumors

Results presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting BASEL, Switzerland – 10th November 2021 – Nouscom, a clinical stage immuno-oncology company developing [...]

Nouscom AG: Abstract on interim results from Phase 1 trial for NOUS-209, an “off-the-shelf” neoantigen cancer vaccine, in MSI-H solid tumors will be presented at SITC

Our abstract “Phase 1 Interim Study Results of Nous-209, an Off-the-Shelf Immunotherapy, with Pembrolizumab, for the Treatment of Tumors with a Deficiency in Mismatch Repair/ Microsatellite [...]

Nouscom announces initial results from Phase 1 trial for NOUS-209, an ‘off-the-shelf’ neoantigen cancer vaccine, in MSI-H solid tumors

Results presented at the European Society of Medical Oncology (ESMO) congress BASEL, Switzerland – 16th September 2021 – Nouscom, a clinical stage immuno-oncology company developing [...]

Nouscom AG: Poster on initial results from Phase 1 trial for NOUS-209, an “off-the-shelf” neoantigen cancer vaccine, in MSI-H solid tumors will be presented at ESMO

Our abstract “Initial Results from a Phase I Study of NOUS-209, an Off-the-Shelf Viral Vectored Immunotherapy Encoding 209 Shared Frame Shift Peptide Neoantigens, with Pembrolizumab, for the [...]

Nouscom announces first patient dosed in a Phase 1b Trial with NOUS-PEV, a novel personalized cancer immunotherapy, in advanced melanoma or lung cancer

BASEL, Switzerland – August 24th, 2021: Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines, today announced that the first [...]

Nouscom receives approval to begin Phase 1b trials of NOUS-PEV, a novel personalized cancer immunotherapy

BASEL, Switzerland – 11th March 2021: Nouscom, a clinical stage immuno-oncology biotech developing next generation viral-vector based immunotherapies, today announces it has received approval [...]

Nouscom appoints Göran Ando MD as Chairman and Richard Davis PhD as Chief Business Officer

BASEL, Switzerland – 11th December 2020: Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized genetic cancer vaccines, today announces that it has appointed [...]

Nouscom highlights cutting-edge science that led to the design of NOUS-209, a potential off-the-shelf neoantigen cancer vaccine for tumors with Microsatellite Instability

Article entitled ‘A genetic vaccine encoding shared cancer neoantigens to treat tumors with Microsatellite Instability’ published in Cancer Research BASEL, Switzerland – 22. July 2020: Nouscom, [...]

Nouscom Strengthens its Management Team

Marina Udier, PhD, appointed as Chief Executive Officer and Patricia Delaite, MD, appointed as Chief Medical Officer BASEL, Switzerland – 26. February 2020: Nouscom, an immuno-oncology company [...]

Nouscom – First Patient Dosed in a Phase 1 Trial with NOUS-209, an ‘off-the-shelf’ Neoantigen Cancer Vaccine, in MSI-High Solid Tumors

BASEL, Switzerland – 9 December 2019: Nouscom, an immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines, announced today that the first patient has been [...]